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Human Wharton’s Jelly MSCs (hWJ-MSCs) have a considerable advantage and potential in treating the cen-
tral nervous system diseases and can be a new alternative treatment of Multiple Sclerosis (MS). Aim. To study 
the persistence and distribution of hWJ-MSCs along the neuraxis following transplantation in central nervous 
system of rats with experimental autoimmune encephalomyelitis (EAE), the animal model of MS. Methods. 
Isolation and cultivation of hWJ-MSCs in vitro. Immunological phenotyping by flow cytometry. EAE induc-
tion. Intrathecal (suboccipital) injection of MSCs into CNS of SCH-induced EAE rats. Persistence of hWJ-
MSCs in the CNS of hWJ-MSCs -treated rats was detected through detection of the human alpha-satellite 
DNA in the tissue sections and the cerebrospinal fluid (CSF) by PCR at days 2, 3, 4 and 5. Results. PCR-assays 
for alpha-satellite sequences revealed that human DNA was detected during 5 days following intrathecal injec-
tion at the peak of disease in the treated rats. It has been demonstrated that the human DNA was traced in CSF 
and various segments of a spinal cord. Conclusions. The data obtained suggest that intrathecally delivered 
hWJ-MSCs, with time, can migrate through the CSF from the injection site to various segments of CNS and 
persist therein during the first week of post transplantation, which was performed at the EAE disease peak in 
the xenogeneic setting without immunosuppression. hWJ-MSCs may be considered as a delivery cell source 
of therapeutic molecules for CNS inflammatory diseases.
K e y w o r d s: hWJ-MSCs, experimental autoimmune encephalomyelitis, alpha-satellite DNA.
Introduction
To date Multiple Sclerosis (MS) is considered as a 
complex and chronic immune-mediated and neuro-
degenerative disease caused by genetic susceptibili-
ty and environmental risk factors [1, 2]. It is charac-
terized by infiltration of immune cells from the 
bloodstream into the central nervous system (CNS) 
and damage of myelin and axons. Over the last years, 
the approaches for MS treating have been developed 
to suppress the immune system for controlling the 
inflammatory process with the aim of the disease 
progression termination. The currently used treat-
ments are only partially effective [3–5]. New cell-
based therapies are needed for neurogenesis or my-
elogenesis of the damaged CSN tissues and recover-
ing the neurological functions [6, 3].
Multiple studies have demonstrated that mesen-
chymal stem cells (MSCs) of different origin are able 
to ameliorate experimental autoimmune encephalo-
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myelitis (EAE), an animal model of MS [5, 7–9]. The 
cells have displayed immunomodulatory, anti-inflam-
matory, pro-regenerative, neuroprotective, and angio-
genic properties in the models of a number of neuro-
logical disorders [10–12] including significant reduc-
tion of spinal cord inflammation and reduced demye-
lination and axonal loss in the EAE lesions [7]. Also, 
in the mouse EAE model, the administration of MSCs 
exhibited dose-dependent protection from EAE in-
duction, and in an established EAE it reduced the dis-
ease progression and severity [7].
It is shown that MSCs can migrate locally into the 
damaged CNS areas where they have the potential to 
support local neurogenesis or myelogenesis through 
the neurotrophic effects, stimulation of resident CNS 
stem cells, induction of in situ immunomodulation, 
or, theoretically, even transdifferentiation [5]. It has 
also been reported that MSCs could function as neu-
rotrophic sources via the cerebrospinal fluid (CSF) 
[13]. Isakova et al. found that human MSCs trans-
planted in brain were dynamically distributed and 
preferentially localized in specific anatomical re-
gions [14], and that this process was likely mediated 
by the neural adhesion molecules and the guidance 
receptors expressed by the transplanted MSCs [15].
The mechanisms of MSC therapy and the novel 
therapeutic strategies for neurological treatments are 
being intensely investigated. The result of the cell-
based therapy depends on many factors, for instance, 
on the choice of the cell type, route of administra-
tion, amount of transplanted cells, time window.
MSCs from the human umbilical cord Wharton’s 
jelly might be effective in the treatment of the cen-
tral nervous system diseases. An immunomodulato-
ry effect of WJ-MSCs was evaluated in vitro and in 
the animal models [16, 17]. For a long time it was 
thought that CNS is an immune-privileged site due 
to its structural features. Nevertheless, the current 
evidences support the idea that CNS is monitored by 
the immune system through a modified surveillance 
circuit and the concept of CNS immune privilege 
should be revised [18]. MS is an example of such 
CNS immune surveillance. The survival and distri-
bution of hWJ-MSCs in CNS under the EAE patho-
logical conditions have not been studied particularly 
since these factors may have a significant impact on 
the efficiency of cell therapy. In this context, our aim 
was to evaluate the hWJ-MSC persistence and post-
transplantation distribution within the affected CNS 
of the immunocompetent EAE-model animals treat-
ed with the cells at the peak of clinical symptoms 
without an appropriate immune suppression.
Materials and Methods
Laboratory animals
Wistar rats (males, weight 180–200 g) were used 
as experimental animals. The animals were housed 
under standard conditions with free access to water 
and food. All animal experiments were done under 
exacting adherence with the low of Ukraine №3447-
IV from 21.02.2006 “The protection of animals from 
cruel behavior” [19] and Guide for the Care and Use 
of laboratory Animals [20]. 
Cell isolation and cultivation
Human MSCs were elaborated from umbilical 
cord as described previously [21]. The cells at sec-
ond passage were harvested and resuspended in 
phosphate buffered saline (PBS), 10 × 106 cells per 
milliliter. A sample of the cells to be injected was 
assessed with BD FACSAria cell sorter (Becton 
Dickinson Biosciences, San Jose, CA, USA) and 
analyzed using BD FACSDiva software (v 6.1.2) to 
confirm proper surface marker expression (CD73, 
CD90, CD105 and CD34) [22].
EAE induction and hWJ-MSC injections
To induce EAE, rats were immunized with inocu-
lums containing a rat spinal cord homogenized (SCH) 
in PBS and emulsified at a ratio of 1:1.6 with Freund’s 
complete adjuvant (Sigma-Aldrich) by the subcutane-
ous injection into hind limb footpads [23]. The EAE 
rats were evaluated according to the grading system 
for clinical assessment of EAE [24]. hWJ-MSCs were 
transplanted intrathecally into the animals through the 
cisterna magna according to the protocols for suboc-
cipital injection. Shortly, anesthetized animals were 
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fixed, the occipital protuberance at the start of the cer-
vical spine was identified for a needle positioning to-
wards the foramen magnum. A needle was carefully 
inserted through the skin until the atlantooccipital 
membrane was punctured. The subdural space posi-
tion was verified by the return of CSF. hWJ-MSCs 
(1x106) in 100 μL PBS were slowly injected to the 
cisterna magna on day 16 after SCH immunization. 
The animals that did not receive hWJ-MSCs served as 
a control. The rats were sacrificed for a post-morten 
analysis at 2, 3, 4 and 5th days after cell transplantation 
(approximately 2–3 rats/group/timepoint).
Isolation of DNA
Genomic DNA was extracted from the cells of 
CSF using the salting out method [25] and from the 
brain and the spinal cord tissues using the method of 
Bruijn et al. [26]. The DNA obtained from untreated 
rat was used as a negative control and DNA from 
hWJ-MSCs was used as a positive control. The DNA 
concentration and purity were determined by optical 
density using the Thermo Scientific Nanodrop 2000 
UV Vis spectrophotometer.
Polymerase chain reaction
The standardised PCR was performed according to 
Becker et al. [27]. All assays were performed in dupli-
cate. Each reaction contained the same amount of ge-
nomic DNA template. The products were visualized 
by electrophoresis in 1.2 % agarose gel. The following 
PCR primers that target a sequence in the alpha-satel-
lite region of the human chromosome 17 were used: 
5_-TGCGCGTGAAGGTTTGCCAGTGT- 3 and 
5_-GCCCCCAGTCGTTCAGGTAATC ATA-
GTCC-3 [28]. 
Results and Discussion
After isolation from Wharton’s jelly, the cultured 
hWJ-MSCs were harvested at the second passage. In 
accordance to FACS analysis more than 90 % of hWJ-
MSCs were positive for CD73, CD90, and CD105 
antigens and negative for CD34 antigen (< 2 %). The 
cells were checked for viability via Trypan blue ex-
clusion, counted using hemocytometer and prepared 
for transplantation in phosphate buffered saline (PBS) 
at a concentration of 10 × 106/mL.
The rats were inoculated according to the immu-
nization protocol, evaluated daily for signs of the 
disease and graded on the scale of 0 to 5 according to 
the severity of the symptoms [24]. It was found that 
immunization resulted in relapsing-remitting disease 
where the rats could have to 3 bouts within the ex-
perimental period. The animals with mean EAE 
score = 2 (total of 46 animals) were selected for the 
MSC treatment. 
It is known, that the route chosen for delivery of 
cells may influence the survival, migration and final 
localisation of the transplanted cells. To avoid the 
system effect under i. v. route of MSC transplanta-
tion and excessive incorporation of the hWJ-MSCs 
into other organs and systems we injected the cells 
into the CNS of EAE-animals. 
It has been demonstrated that upon the transplan-
tation into CNS, the cells may circulate with the flow 
of the cerebrospinal fluid and reach the affected CNS 
areas [5]. To follow the fate and the distribution of 
the hWJ-MSCs throughout the neuraxis of animals, 
four tissue CNS sections (cerebral hemispheres, 
brainstem within the region of injection, spinal cord 
from thoracic and lumbar regions) and CSF were 
overtime collected for isolation of genomic DNA at 
each time point (2nd,3rd, 4th and 5th days post trans-
plantation). The volume of CSF collected by direct 
cisterna magna puncture was nearly 100 μl. The ce-
rebral hemispheres, brainstem, and spinal cord were 
taken out and successive sections of them were 
sliced. To identify human cells, we used PCR assay 
for human-specific alpha-satellite sequence for con-
firmation [28]. To facilitate the PCR-assay the same 
amounts of DNA were used for every reaction. The 
sensitivity of the assay was about 1 human cell per 
105 murine cells, as proved by logarithmic dilution 
steps of hMSCs in rat splenocytes. The assays for 
human alpha-satellite sequences indicated that the 
human DNA was detected throughout the study pe-
riod (5 days) following the injection without an ap-
propriate immune suppression. Table 1 provides a 
summarized picture of the PCR-assays.
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As to an anatomical location, it has been demon-
strated that the transplanted hWJ-MSCs can migrate 
through CSF. The representative examples of mo-
lecular detection of hWJ-MSCs in various segments 
of the spinal cord, CSF, brainstem, and cerebral 
hemispheres are presented in Fig. 1–5. As shown in 
Fig. 1, all tissue samples of brainstem within the re-
gion of injection were positive for the human DNA. 
Probably, the majority of hWJ MSCs are initially 
trapped in this region and persisted there throughout 
all study period.
The human DNA was also detected in CSF from 
cisterna magna in the majority of samples (Fig. 2).
It is known, that intrathecal route for the cell de-
livery in neurological disease such as MS character-
ized by zones of tissue damage localised along the 
neuraxis, may promote migration of the injected 
cells to the proximity of the CNS lesions. Figure 3 
illustrates that hWJ-MSCs may penetrate the neigh-
bouring thoracic region of spinal cord.
Oppositely, Figures 4 and 5 demonstrate that al-
pha-satellite sequences were not detected in cerebral 
and lumbar regions of spinal cord with the exception 
of a single case. Possibly, major portion of the cells 
died during the first day after transplantation due to 
hypoxia and serum deprivation following transplan-
tation and the cell amount was insufficient to induce 
positive PCR signal. The second variant, the cells 
did not penetrate to these regions. Another possible 
explanation is a small number of animals in each 
group. It is possible that with increased amount of 
rats the results may be different.
As some MS lesions remyelinate spontaneously 
and unpredictably, the timing of MSCs administra-
tion is very important but difficult to be determined. 
In the clinical setting, the cell-based treatment is 
usually applied only when MS is in progress. In this 
respect, despite the efficiency of preventive MS 
treatment with MSCs in animal models, it is of ther-
apeutic importance that MSCs were also effective 
when administered to animals with established dis-
ease. Therefore we studied the retention and distri-
bution of the intrathecally injected hWJ-MSCs in the 
EAE rats at delayed cell administration. 
Table 1. hWJ-MSC detection by alpha-satellite DNA PCR
Point transplantation 
time
2 days
n = 2
3 days
n = 2
4 days
n = 2
5 days
n = 2
Cerebral hemispheres 1 0 0 0
Brainstem within the 
region of injection 2 2 2 2
CSF (cerebrospinal 
fluid) 
2 2 1 1
Spinal cord from 
thoracic region 2 2 2 2
Spinal cord from 
lumbar region 0 0 0 0
PCR-positive rats at each post-transplantation time point are 
shown. 
 1 2 3 4 5 6 7 8 9 10
Fig. 1. The results of PCR for the presence of alpha-human 
DNA samples from brainstem of rats within the region of injec-
tion after administration of hWJ-MSCs at different post-trans-
plantation time intervals. 1 – 2 days; 2 – 2 days; 3 – 3 days; 4 – 
3 days; 5 – molecular weight marker, 1 kb DNA Ladder (Fer-
mentas); 6 – 4 days; 7 – 4 days; 8 – 5 days; 9 – 5 days; 10 – hu-
man MSC DNA (positive control)
 1 2 3 4 5 6 7 8 9
Fig. 2. The results of PCR for the presence of alpha-human 
DNA samples from CSF of rats after administration of hWJ-
MSCs at different time intervals of post-transplantation. 1 – 
2 days; 2 – 3 days; 3 – 3 days; 4 – 4 days; 5 – 4 days; 6 – mo-
lecular weight marker, 1 kb DNA Ladder (Fermentas); 7 – 5 
days; 8 – 5 days; 9 – human MSC DNA (positive control)
 
 1 2 3 4 5 6 7 8 9 10
Fig. 3. The results of PCR for the presence of alpha-human 
DNA samples from thoracic region of rat spinal cord after 
administration of hWJ-MSCs at different time intervals of post-
transplantation. 1 – 2 days; 2 – 2 days; 3 – 3 days; 4 – 3 days; 
5 – molecular weight marker, 1 kb DNA Ladder (Fermentas); 
6 – 4 days; 7 – 4 days; 8 – 5 days; 9 – 5 days; 10 – human MSC 
DNA (positive control)
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Generally, these data have shown that human WJ-
MSCs injected into the EAE rats at the peak of dis-
ease were allocated to the specific regions within the 
CNS of treated animals. During one week they were 
widely distributed along the neuraxis. Possibly, these 
cells can penetrate into the inflamed spinal cord and 
persist there for some time in the xenogeneic setting 
without immunesuppression. In contrast to these re-
sults, dissimilar survival features of the same hWJ-
MSCs have been revealed in another rat model (ex-
perimental osteoarthritis) after injecting the cells 
into a knee joint, where human DNA was detected 
only at the first day after the injection [29]. The re-
sults obtained in the present study are in line with the 
earlier reports [7, 14].
It should be noted that PCR detection of the hu-
man-specific DNA sequences in the animal model 
does not give direct confirmation of the cell viability. 
Nevertheless, there is a close correlation between the 
cell viability and the possibility to detect a specific 
DNA sequence by PCR [30]. Comprehensive ap-
proaches are required for a direct confirmation of the 
cell presence and the cell viability following the 
transplantation. Most likely, the therapeutic effect of 
MSCs could be enhanced by extending their persis-
tence after the transplantation. There is relatively 
large amount of studies that assess a fate of the trans-
planted cells in the models of a number of neuro-
logical disorders. However, a direct comparison of 
the experimental results is difficult due to the differ-
ences in the cell source, passages, delivery route, 
cell dose, recipient species, cell labelling and detect-
ing method, environment, etc. Chang-Ching Yang et 
al. [31] used anti-human specific nuclear antigen im-
munostaining to trace the survival and migration 
pattern of the hWJ-MSCs in the repair of rat spinal 
cord injury. Numerous hWJ-MSCs survived for at 
least four months after the transplantation according 
to the data obtained with the immunohistochemical 
analysis. In another study Forostyak et al. researched 
the survival and fate of the intrathecally delivered 
the human MSCs within CNS of the amyotrophic 
lateral sclerosis rats [31]. To determine the survival 
and the fate of the grafted cells, the spinal cord sec-
tions were stained with the human-specific markers 
for mitochondria (MtC02) and nuclei (HuNu). It was 
shown that despite adequate immunosuppression, 
the transplanted MSCs did not survive in the CNS or 
subdural space of the affected rats at the 14th day of 
post transplantation though the cells ameliorated the 
disease progression. In parallel experiment, in which 
the same number of rat MSCsGFP+ was delivered into 
rats, already 14 days after the transplantation the 
GFP-positive cells could not be detected in the spi-
nal cord and brain.
The literature data have shown that CSF also can 
influence the fate of the transplanted cells. Farivar et 
al. studied the effect of human CSF on the neural 
differentiation of hWJ-MSCs in vitro. It was shown 
by an expression analysis for the known neural 
markers (Nestin, GFAP, and MAP2) that CSF in-
duced the neurogenesis of hWJ-MSCs [32]. 
However, there are also arguments that the CSF 
composition under the pathological conditions and 
exogenous environment limit the survival of the 
transplanted MSCs [31]. To date, the mechanisms 
 1 2 3 4 5 6 7 8 9 10 11
Fig. 4. The results of PCR for the presence of alpha-human 
DNA samples from rat cerebrum after administration of hWJ-
MSCs at different time intervals of post-transplantation. 1 – rat 
leukocyte DNA (negative control); 2 – 2 days; 3 – 2 days; 4 – 
3 days; 5 – 3 days; 6 – molecular weight marker, 1 kb DNA 
Ladder (Fermentas); 7 – 4 days; 8 – 4 days; 9 – human MSC 
DNA (positive control); 10 – 5 days; 11 – 5 days
 1 2 3 4 5 6 7 8 9 10 11
Fig. 5. The results of PCR for the presence of alpha-human 
DNA samples from spinal cord from lumbar region of rat spinal 
cord after administration of hWJ-MSCs at different time 
intervals of post-transplantation. 1 – rat leukocyte DNA (nega-
tive control); 2 – 2 days; 3 – 2 days; 4 – 3 days; 5 – 3 days; 6 – 
molecular weight marker, 1 kb DNA Ladder (Fermentas); 7 – 
4 days; 8 – 4 days; 9 – human MSC DNA (positive control); 
10 – 5 days; 11 – 5 days
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underlying elimination of the transplanted MSCs by 
a host also require more thorough researches. In this 
context, the present study revealed that the intrathe-
cally delivered hWJ-MSCs in the EAE rats were dis-
tributed across the affected CNS, overcame a trans-
plantational shock and persisted during the initial 
days following transplantation. Assuming that ac-
cording to the “hit-run mechanism” hypothesis, the 
long-term survival of the MSCs is not critical for 
their therapeutic activity, the cells can be used to de-
liver several therapeutic agents (growth factors, cy-
tokines, etc.) into CNS. To determine how long 
hWJ-MSCs could persist in the CNS under the EAE 
pathological conditions, the additional long-term 
studies are needed.
Conclusions
The data obtained suggest that the intrathecally de-
livered hWJ-MSCs, with time, can migrate through 
the CSF from the injection site to various segments of 
CNS and persist therein during the first week post 
transplantation, which was performed at the EAE 
disease peak in the xenogeneic setting without im-
munosuppression. hWJ-MSCs may be considered as 
the delivery cell source of the therapeutic molecules 
for the cure of the CNS inflammatory diseases.
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Розподіл трансплантованих МСК Вартонового студня 
пуповини людини в центральній нервовій системі 
щурів з експериментальним аутоімунним 
енцефаломієлом
М. В. Ковальчук, О. Г. Дерябіна, Л. Д. Пічкур, 
С. А. Вербовська, Н. С. Шувалова, О. Л. Пічкур, 
В. А. Кордюм
Мезенхімальні стовбурові клітини Вартонового студня пупо-
вини людини (МСК-ВС) мають значну перевагу і потенціал у 
лікуванні захворювань центральної нервової системи (ЦНС) і 
можуть стати новою альтернативною терапією для розсіяного 
склерозу (РС). Мета. Вивчити виживання і розподіл МСК-ВС 
в ЦНС щурів з ЕAЕ після субокціпітальної трансплантації. 
Методи. Виділення і культивування МСК-ВС in vitro. 
Імунологічне фенотипування методом проточної цитофлюори-
метрії. Індукція ЕАЕ. Інтратекальне введення МСК в ЦНС щу-
рів лінії Wistar з ЕАЕ, індукованим гомогенатом спинного моз-
ку (ГСМ). Виживання МСК-ВС в ЦНС щурів оцінювали за 
допомогою виявлення людської альфа-сателітної ДНК у зраз-
ках тканин та спинномозковій рідині (СМР) на 2, 3, 4, та 5 дні 
за допомогою ПЛР. Результати. ПЛР-аналіз для альфа-сателіт-
них послідовностей показав, що ДНК людини виявлялася про-
тягом 5 днів після інтратекального введення, на піку симпто-
мів. Було показано, що трансплантовані ксеногенні МСК-ВС 
мігрували через СМР в різні сегменти спинного мозку. 
Висновки. Отримані результати дозволяють припустити, що 
МСК-ВС, введені інтратекально, можуть мігрувати зі струмом 
СМР в різні відділи ЦНС і перебувати в них протягом першого 
тижня після трансплантації на піку захворювання ЕAЕ в ксе-
ногенному варіанті без імуносупресії. МСК-ВС можна розгля-
дати як джерело клітин для доставки терапевтичних молекул 
для лікування запальних захворювань ЦНС.
К л юч ов і  с л ов а: МСК-ВС, експериментальний аутоімун-
ний енцефаломієліт, альфа-сателітна ДНК.
Распределение трансплантированных МСК 
Вартонового студня пуповины человека в центральной 
нервной системе крыс с экспериментальным 
аутоиммунным энцефаломиелитом
М. В. Ковальчук, Е. Г. Дерябина, Л. Д. Пичкур, 
С. А. Вербовская, Н. С. Шувалова, А. Л. Пичкур, 
В. А. Кордюм
Мезенхимальные стволовые клетки Вартонового студня пупо-
вины человека (МСК-ВС) имеют значительное преимущество 
перед другими видами стволовых клеток и потенциал в лече-
нии заболеваний центральной нервной системы (ЦНС) и мо-
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гут стать новой альтернативной терапией для рассеянного 
склероза. Цель. Изучить выживание и распределение МСК-
ВС в ЦНС крыс с ЭАЭ после субоксипитальной транспланта-
ции. Методы. Выделение и культивирование МСК-ВС in vitro. 
Иммунологическое фенотипирование методом проточной ци-
тофлюориметрии. Индукция ЭАЭ. Интратекальное (субокци-
питальное) введение МСК в ЦНС крыс линии Wistar с ЭАЭ, 
индуцированным гомогенатом спинного мозга (ГСМ). 
Выживание МСК-ВС в ЦНС крыс оценивали с помощью вы-
явления человеческой альфа-сателлитной ДНК в образцах тка-
ней и спинномозговой жидкости (СМЖ) на 2, 3, 4 и 5 дни с 
помощью ПЦР. Результаты. ПЦР-анализ для альфа-сателлит-
ных последовательностей показал, что ДНК человека обнару-
живалась в течение 5 дней после интратекального введения, на 
пике симптомов. Было показано, что трансплантированные 
ксеногенные МСК-ВС мигрировали через спинномозговую 
жидкость (СМЖ) в различные сегменты спинного мозга. 
Выводы. Полученные результаты позволяют предположить, 
что МСК-ВС, введенные интратекально, со временем¸могут 
мигрировать с током СМЖ в различные отделы ЦНС и нахо-
диться в них на протяжении первой недели после транспланта-
ции на пике заболевания ЭAЭ в ксеногенном варианте без им-
муносупрессии. МСК-ВС можно рассматривать как источник 
клеток для доставки терапевтических молекул для лечения 
воспалительных заболеваний ЦНС.
К л юч е в ы е  с л ов а: МСК-ВС, экспериментальный ауто-
иммунный энцефаломиелит, альфа-сателлитная ДНК. 
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